In August 2026, Taobao Flash Sale launched cold-chain medicine delivery in six Chinese cities using disposable insulated boxes, temperature control, and traceability. Instant retail must now ensure temperature, timeliness, traceability, and exception handling after medicines leave stores. China’s pharmaceutical circulation grew only 0.54% in 2025, but cold-chain infrastructure and pharma O2O are expanding faster. The last mile is hardest: orders are random, small, scattered, and temperature-sensitive, requiring prescription review, real-name purchase, compliant packaging, and records. Disposable boxes aid expansion but not full quality responsibility. High growth brings costs—monitoring, packaging, pharmacist review, training, after-sales. Pharmacies become cold-chain nodes. Competition shifts from speed to verifiable evidence. The moat is integrating compliance, fulfillment, and quality systems to make every cold-chain delivery safe, compliant, traceable, and cost-effective.